Takeda Pharmaceutical Company Limited
4502.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$56.83B
Close$
Share Statistics
| Market cap | $56.83 Billion |
|---|---|
| Enterprise Value | $4.65 Trillion |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 2.41% |
|---|---|
| Return on Assets | 1.16% |
| Return on Invested Capital | 5.02% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1 |
| Enterprise Value to EBIT | 7.19 |
| Enterprise Value to Net Income | 25 |
| Total Debt to Enterprise | 1.09 |
| Debt to Equity | 0.67 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$53.12
Average shareholder expectationRevenue Estimate
$1149.59 B
Average shareholder expectationNext Earnings Call
Expected Date
October 29, 2026
EPS Estimate
$45.95
Average shareholder expectationRevenue Estimate
$1154.20 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Takeda Pharmaceutical Co
47,029 employees
CEO: Christophe Weber Takeda Pharmaceutical Company Limited is a global biopharmaceutical enterprise engaged in the discovery, development, manufacturing, marketing, and out-licensing of various medical products. The company's operations span Japan, the Unite...